nach oben

Erschienen in:

01.02.2013 | Original Communication

A randomized clinical trial of lithium in multiple system atrophy

verfasst von: Francesco Saccà, Angela Marsili, Mario Quarantelli, Vincenzo Brescia Morra, Arturo Brunetti, Rosa Carbone, Chiara Pane, Giorgia Puorro, Cinzia Valeria Russo, Elena Salvatore, Tecla Tucci, Giuseppe De Michele, Alessandro Filla

Erschienen in: Journal of Neurology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of our study was to test the safety and tolerability of lithium in multiple system atrophy (MSA). The study was randomized, placebo-controlled, and double-blind. The primary endpoint of the study was safety and tolerability. An interim analysis, performed 1 year after the first patient was randomized, showed a higher proportion of trial abandon (P < 0.01) and a higher number of adverse events (P < 0.02) in the lithium group. The trial was stopped by the Data Monitoring Committee. Overall, lithium was not well tolerated, and we do not encourage future studies with lithium in MSA patients.

Quinn N (1989) Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatry (suppl):78–89

Sarkar S, Floto RA, Berger Z et al (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170:1101–1111PubMedCrossRef

Webb JL, Ravikumar B, Atkins J et al (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009–25013PubMedCrossRef

Sarkar S, Krishna G, Imarisio S et al (2008) A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet 17:170–178PubMedCrossRef

Verstraete E, Veldink JH, Huisman MH et al (2012) Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 83:557–564PubMedCrossRef

Al-Chalabi A, Shaw PJ, Young CA et al (2011) Protocol for a double-blind randomized placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) (Eudract number: 2008-006891-31). BMC Neurol 11:111PubMedCrossRef

Miller RG, Moore DH, Forshew DA et al (2011) Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 77:973–979PubMedCrossRef

Aggarwal SP, Zinman L, Simpson E et al (2010) Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:481–488PubMedCrossRef

Forlenza OV, Diniz BS, Radanovic M et al (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198:351–356PubMedCrossRef

10.

Wenning GK, Tison F, Seppi K et al (2004) Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 19:1391–1402PubMedCrossRef

11.

Beck AT, Steer RA, Brown GK et al (1996) BDI-II—beck depression inventory, 2nd edn. The Psychological Corporation Harcourt Brace and Company, San Antonio

12.

Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676PubMedCrossRef

13.

Holmberg B, Johansson JO, Poewe W, Growth-Hormone MSA Study Group; European MSA Study Group et al (2007) Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 22:1138–1144PubMedCrossRef

14.

Dodel R, Spottke A, Gerhard A et al (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11) C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25:97–107PubMedCrossRef

Titel: A randomized clinical trial of lithium in multiple system atrophy
verfasst von: Francesco Saccà
Angela Marsili
Mario Quarantelli
Vincenzo Brescia Morra
Arturo Brunetti
Rosa Carbone
Chiara Pane
Giorgia Puorro
Cinzia Valeria Russo
Elena Salvatore
Tecla Tucci
Giuseppe De Michele
Alessandro Filla
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: Journal of Neurology / Ausgabe 2/2013
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6655-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A randomized clinical trial of lithium in multiple system atrophy

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Future MS care: a consensus statement of the MS in the 21st Century Steering Group

Communication of the European Neurological Society

Crossed cerebellar hyperperfusion without restricted diffusion in status epilepticus

Treatment deviating from guidelines does not influence status epilepticus prognosis

A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures

Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitors

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie